All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Checkpoint Therapeutics Inc., a subsidiary of Fortress Biotech Inc., has big plans. During September the company will launch a phase I/II trial of its third-generation EGFR inhibitor CK-101 in non-small-cell lung cancer and, around the same time, a public market listing.